# TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

> **NCT02676076** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 1153 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** CHF 5993 100/6/12.5 µg
- **DRUG:** CHF 1535 100/6 µg

## Key facts

- **NCT ID:** NCT02676076
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-17
- **Primary completion:** 2018-05-17
- **Final completion:** 2018-05-17
- **Target enrollment:** 1153 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02676076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02676076, "TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02676076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*